Abstract
Anti-Ro/SSA antibodies, which were described for the first time in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS), are the most prevalent extractable nuclear antigen (ENA) specificity identified in laboratories. Two types of anti-Ro/SSA antibodies have been described, anti-SSA-52. kDa (aSSA52) and anti-SSA-60. kDa (aSSA60), each specific to different antigens. Anti-Ro/SSA52 autoantibodies are more frequent than other autoantibodies possibly because of the antigen's accessible and ubiquitous nature. The sites involved and the symptoms associated with these autoantibodies depend on the antigen's structural variability. Isolated congenital complete atrioventricular block (CAVB) shows a close association with maternal anti-Ro/SSA and anti-La/SSB antibodies; the highest relative risks of CAVB are seen in offspring of mothers with antibodies against 52-kDa Ro and 48-kDa La proteins. Anti-Ro/SSA52 antibodies have little impact on adult rheumatic autoimmune diseases or adult cardiac arrhythmias, but the course of autoimmune liver diseases is greatly worsened by their presence, and solid tumours tend to relapse. Their diagnostic role in rheumatic diseases is controversial, although a significant association between isolated anti-Ro/SSA52-kDa positivity and myositis and to a lesser extent with systemic sclerosis (SSc) has been described. However, the majority of the specific diagnosis is mostly based on the simultaneous presence of other autoantibodies that seems diagnostically more relevant.
| Original language | English |
|---|---|
| Pages (from-to) | 150-154 |
| Number of pages | 5 |
| Journal | Autoimmunity Reviews |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 2011 |
Fingerprint
Keywords
- Anti-Ro/SSA52 autoantibodies
- Autoimmune hepatitis
- Cardiac rhythm disorders
- Extractable nuclear antigens
- Primary biliary cirrhosis
- Sjögren's syndrome
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. / Defendenti, Caterina; Atzeni, Fabiola; Spina, Maria Francesca; Grosso, Silvia; Cereda, Aldo; Guercilena, Giacinto; Bollani, Simona; Saibene, Simone; Sarzi-Puttini, Piercarlo.
In: Autoimmunity Reviews, Vol. 10, No. 3, 01.2011, p. 150-154.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical and laboratory aspects of Ro/SSA-52 autoantibodies
AU - Defendenti, Caterina
AU - Atzeni, Fabiola
AU - Spina, Maria Francesca
AU - Grosso, Silvia
AU - Cereda, Aldo
AU - Guercilena, Giacinto
AU - Bollani, Simona
AU - Saibene, Simone
AU - Sarzi-Puttini, Piercarlo
PY - 2011/1
Y1 - 2011/1
N2 - Anti-Ro/SSA antibodies, which were described for the first time in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS), are the most prevalent extractable nuclear antigen (ENA) specificity identified in laboratories. Two types of anti-Ro/SSA antibodies have been described, anti-SSA-52. kDa (aSSA52) and anti-SSA-60. kDa (aSSA60), each specific to different antigens. Anti-Ro/SSA52 autoantibodies are more frequent than other autoantibodies possibly because of the antigen's accessible and ubiquitous nature. The sites involved and the symptoms associated with these autoantibodies depend on the antigen's structural variability. Isolated congenital complete atrioventricular block (CAVB) shows a close association with maternal anti-Ro/SSA and anti-La/SSB antibodies; the highest relative risks of CAVB are seen in offspring of mothers with antibodies against 52-kDa Ro and 48-kDa La proteins. Anti-Ro/SSA52 antibodies have little impact on adult rheumatic autoimmune diseases or adult cardiac arrhythmias, but the course of autoimmune liver diseases is greatly worsened by their presence, and solid tumours tend to relapse. Their diagnostic role in rheumatic diseases is controversial, although a significant association between isolated anti-Ro/SSA52-kDa positivity and myositis and to a lesser extent with systemic sclerosis (SSc) has been described. However, the majority of the specific diagnosis is mostly based on the simultaneous presence of other autoantibodies that seems diagnostically more relevant.
AB - Anti-Ro/SSA antibodies, which were described for the first time in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS), are the most prevalent extractable nuclear antigen (ENA) specificity identified in laboratories. Two types of anti-Ro/SSA antibodies have been described, anti-SSA-52. kDa (aSSA52) and anti-SSA-60. kDa (aSSA60), each specific to different antigens. Anti-Ro/SSA52 autoantibodies are more frequent than other autoantibodies possibly because of the antigen's accessible and ubiquitous nature. The sites involved and the symptoms associated with these autoantibodies depend on the antigen's structural variability. Isolated congenital complete atrioventricular block (CAVB) shows a close association with maternal anti-Ro/SSA and anti-La/SSB antibodies; the highest relative risks of CAVB are seen in offspring of mothers with antibodies against 52-kDa Ro and 48-kDa La proteins. Anti-Ro/SSA52 antibodies have little impact on adult rheumatic autoimmune diseases or adult cardiac arrhythmias, but the course of autoimmune liver diseases is greatly worsened by their presence, and solid tumours tend to relapse. Their diagnostic role in rheumatic diseases is controversial, although a significant association between isolated anti-Ro/SSA52-kDa positivity and myositis and to a lesser extent with systemic sclerosis (SSc) has been described. However, the majority of the specific diagnosis is mostly based on the simultaneous presence of other autoantibodies that seems diagnostically more relevant.
KW - Anti-Ro/SSA52 autoantibodies
KW - Autoimmune hepatitis
KW - Cardiac rhythm disorders
KW - Extractable nuclear antigens
KW - Primary biliary cirrhosis
KW - Sjögren's syndrome
UR - http://www.scopus.com/inward/record.url?scp=78751610989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751610989&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2010.09.005
DO - 10.1016/j.autrev.2010.09.005
M3 - Article
VL - 10
SP - 150
EP - 154
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 3
ER -